Rep. Chris Collins’ enthusiastic investments in Australian biotech company Innate Immunotherapeutics preceded share purchases by the Buffalo Republican’s family members, associates and political donors — raising questions from Washington, D.C., to Sydney.
Pricey and unproven therapies that sound too good to be true probably are.
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
Some clinics on NIH’s website charge people to participate in testing of unproven treatments — and it can come as a surprise to unsuspecting patients.
California is the first state to begin building an up-to-date database to improve the diagnosis and treatment of cancer.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, recently spoke with KHN’s Carmen Heredia Rodriguez about vaccine development and the ongoing fight in Congress over emergency funding.
Despite the usual view that physicians are slow to alter their routines based on new scientific evidence, researchers found that breast cancer surgeons quickly adopted advice to not remove lymph nodes after a landmark clinical trial in 2011.
Treatments marketed as everything from anti-aging applications to therapies for degenerative diseases are increasingly available at commercial clinics in the U.S., but their growing numbers raise ethical and regulatory concerns in the scientific community.
The Food and Drug Administration has introduced a simplified form that doctors will use to seek FDA approval to treat seriously ill patients with experimental drugs after other options run out.
Experimental drugs might help desperate patients, but don’t count on an easy cure.
Clinical trials should look at whether men and women are affected differently, but the NIH isn’t holding researchers accountable, a new report says.
A federal institute created by the health law is seeding research projects around the U.S. that connect medical professionals with patients to find better treatments.
Insurance generally covers routine costs patients encounter in a clinical trial, but the patients can still be responsible for co-payments and other expenses, such as lost wages and travel.
Essure has generated more than 5,000 complaints of serious side effects.